Kymera Therapeutics attracts $65 mln Series B

Cambridge, Massachusetts-based Kymera Therapeutics Inc, a biotechnology company, has closed $65 million in Series B financing. The lead investors were 6 Dimensions Capital, Bessemer Venture Partners and Pfizer Ventures.

ManagersNorth AmericaUSHealthcareBriefs